<bill session="113" type="h" number="3473" updated="2014-08-14T13:21:03-04:00">
  <state datetime="2013-11-13">REFERRED</state>
  <status>
    <introduced datetime="2013-11-13"/>
  </status>
  <introduced datetime="2013-11-13"/>
  <titles>
    <title type="short" as="introduced">Qualifying Therapeutic Discovery Project Tax Credit Extension Act of 2013</title>
    <title type="official" as="introduced">To amend the Internal Revenue Code of 1986 to permanently extend the qualifying therapeutic discovery project credit, and for other purposes.</title>
  </titles>
  <sponsor thomas_id="01641"/>
  <cosponsors>
    <cosponsor thomas_id="01889" joined="2013-11-13"/>
    <cosponsor thomas_id="01959" joined="2013-11-13"/>
    <cosponsor thomas_id="01498" joined="2013-12-04"/>
    <cosponsor thomas_id="02113" joined="2013-12-04"/>
    <cosponsor thomas_id="01798" joined="2013-11-13"/>
    <cosponsor thomas_id="02112" joined="2013-11-13"/>
  </cosponsors>
  <actions>
    <action datetime="2013-11-13" state="REFERRED">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSWM" name="House Ways and Means" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
    <term name="Business investment and capital"/>
    <term name="Income tax credits"/>
    <term name="Inflation and prices"/>
    <term name="Medical research"/>
  </subjects>
  <amendments/>
  <summary>11/13/2013--Introduced.
Qualifying Therapeutic Discovery Project Tax Credit Extension Act of 2013 - Amends the Internal Revenue Code to make permanent the authority to invest in and allocate credit amounts for a qualifying therapeutic discovery project (a project that is designed to: (1) treat or prevent diseases by conducting pre-clinical activities, clinical trials, and clinical studies or by carrying out research projects to approve new drugs or other biologic products; (2) diagnose diseases or conditions to determine molecular factors related to diseases or conditions; or (3) develop a product, process, or technology to further the delivery or administration of therapeutics). Extends the $1 billion allocation for such credit for each 2-year period beginning after 2013 and provides for a biennial inflation adjustment to such allocation amount after 2015.</summary>
</bill>
